CD105 Antibody - #DF7735

(3)   (3)  
製品: CD105 Antibody
カタログ: DF7735
タンパク質の説明: Rabbit polyclonal antibody to CD105
アプリケーション: WB
Cited expt.: WB
反応性: Human, Mouse
予測: Pig, Horse, Sheep, Dog
分子量: 95 kDa; 71kD(Calculated).
ユニプロット: P17813
RRID: AB_2841203

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:1000-3000
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse
予測:
Pig(90%), Horse(90%), Sheep(90%), Dog(80%)
クローナリティ:
Polyclonal
特異性:
CD105 Antibody detects endogenous levels of total CD105.
RRID:
AB_2841203
引用形式: Affinity Biosciences Cat# DF7735, RRID:AB_2841203.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

AI528660; AI662476; CD 105; CD105; CD105 antigen; EGLN_HUMAN; END; Endoglin; Eng; FLJ41744; HHT1; ORW; ORW1; Osler Rendu Weber syndrome 1; RP11 228B15.2; S-endoglin; SN6;

免疫原

免疫原:

A synthesized peptide derived from human CD105, corresponding to a region within the internal amino acids.

Uniprot:

P17813(EGLN_HUMAN) >>Visit HPA database.

遺伝子(ID):
ENG(2022)
発現特異性:
P17813 EGLN_HUMAN:

Detected on umbilical veil endothelial cells (PubMed:10625079). Detected in placenta (at protein level) (PubMed:1692830). Detected on endothelial cells (PubMed:1692830).

タンパク質配列:
MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
90
Horse
90
Sheep
90
Dog
80
Rabbit
78
Bovine
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

機能:

Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis. Required for normal structure and integrity of adult vasculature. Regulates the migration of vascular endothelial cells. Required for normal extraembryonic angiogenesis and for embryonic heart development (By similarity). May regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and establishment of normal vascular morphology during angiogenesis (By similarity). May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Acts as TGF-beta coreceptor and is involved in the TGF-beta/BMP signaling cascade that ultimately leads to the activation of SMAD transcription factors. Required for GDF2/BMP9 signaling through SMAD1 in endothelial cells and modulates TGFB1 signaling through SMAD3.

細胞の位置付け:

Cell membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Detected on umbilical veil endothelial cells. Detected in placenta (at protein level). Detected on endothelial cells.

タンパク質ファミリー:

The ZP domain mediates dimerization.

The N-terminal OR region is composed of two intertwined domains (OR1 and OR2) with a common, novel fold. Each contains 12 beta-strands that form a parallel beta-helix-like structure, plus a single alpha-helix. The OR1 region mediates interaction with GDF2.

参考文献

1). EphrinB2 overexpression enhances osteogenic differentiation of dental pulp stem cells partially through ephrinB2-mediated reverse signaling. Stem Cell Research & Therapy, 2020 (PubMed: 31996240) [IF=7.5]

Application: IF/ICC    Species: canine    Sample: cDPSCs

Fig. 5 Culture, characterization, and transfection of cDPSCs and proliferation of cDPSCs in PuraMatrix. a Cell colonies stained with crystal violet. b, c Verification of osteogenic, adipogenic, and neurogenic differentiation capabilities of cDPSCs. Scale bar of left and right images, 100 μm; scale bar of middle images, 50 μm. *p < 0.05 and **p < 0.01. d Stem cell markers of cDPSCs. Scale bar = 1 mm. e, f Verification of green fluorescence expression and ephrinB2 upregulation in transfected cDPSCs. Scale bar = 100 μm. **p < 0.01. g Alizarin Red S staining of cDPSCs, Vector-cDPSCs (ephrinB2 overexpression control), and EfnB2-cDPSCs (ephrinB2 overexpression) on day 24 of osteogenesis. h Alizarin Red S staining intensity was quantified with ImageJ. *p < 0.05. i Proliferation of cDPSCs (1 × 106 cells/ml) in 0.5%, 0.25%, and 0.125% PuraMatrix. *p < 0.05 and **p < 0.01 vs. 0.25% PuraMatrix; # p < 0.05 and ## p < 0.01 vs. 0.125% PuraMatrix. j Proliferation of cDPSCs at different cell densities (0.25, 0.5, 1, 2, or 4 × 106 cells/ml) in 0.25% PuraMatrix. Data are shown as mean ± SD. Assays were repeated three times

Application: IF/ICC    Species: beagles    Sample: cDPSCs

Fig. 5 | Culture, characterization, and transfection of cDPSCs and proliferation of cDPSCs in PuraMatrix. a Cell colonies stained with crystal violet. b,c Verification of osteogenic, adipogenic, and neurogenic differentiation capabilities of cDPSCs. Scale bar of left and right images, 100 μm; scale bar of middle images, 50 μm. *p < 0.05 and **p < 0.01. d Stem cell markers of cDPSCs. Scale bar = 1 mm.
2). Zingerone treats postmenopausal osteoporosis via increased ferroptosis sensitivity by p53-mediated regulation of SAT1 and GPX4 expression. Communications biology, 2025 (PubMed: 41006700) [IF=5.9]
3). Effect of Sonic hedgehog gene-modified bone marrow mesenchymal stem cells on graft-induced retinal gliosis and retinal ganglion cells survival in diabetic mice. International journal of ophthalmology, 2024 (PubMed: 38239953) [IF=1.9]

Application: WB    Species: Mouse    Sample:

Figure 1. Characterization of MSCs and transduction of MSC-Shh. Immunofluorescence indicated that MSCs exhibited a characteristic immunophenotype of high expressed CD44. The Shh gene expression was observed by measuring the tagged protein GFP with immunofluorescence (A). The Western blot assay showed that the protein level of Shh increased significantly in MSC-Shh compared with the control of MSC-Gfp (B). The Western blot assay showed the expression of CD73 and CD105 of MSC-Shh and the control MSC-Gfp (C). The morphological characteristics of MSC-Shh and MSC-Gfp was assessed (D). MSCs: Mesenchymal stem cells. MSC-Shh: Shh-modified MSCs; MSC-Gfp: Green fluorescent protein-modified MSCs.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.